Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease

Next Previous
X
Search
Trial Profile

A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tavapadon (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 23 Sep 2019 Primary endpoint (Change from baseline in the Modified Unified Parkinsons Disease Rating Scale (MDS UPDRS) Score Part III at week 15, evaluating motor symptoms: tavapadon compared with placebo) has been met, according to a Cerevel Therapeutics media release.
    • 23 Sep 2019 According to a Cerevel Therapeutics media release, results of this study are being presented today at the 2019 International Congress of Parkinsons Disease and Movement Disorders (Nice, France) by David Gray, Ph.D., vice president of chemistry at Cerevel Therapeutics and this study team leader, during a poster presentation session.
    • 23 Sep 2019 Results presented in a Cerevel Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top